The role of BRCA1 in DNA double-strand repair: Past and present

Experimental Cell Research

Volumn 319, Issue 5, 2013, Pages 575-587

  Caestecker, Kevin W ^a   Van de Walle, Gerlinde R ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

BRCA1; Breast cancer; DNA repair; Interacting proteins; PARP inhibitors

Indexed keywords

BRCA1 PROTEIN; DNA TOPOISOMERASE II BINDING PROTEIN; DOUBLE STRANDED DNA; FANCONI ANEMIA GROUP D2 PROTEIN; UNCLASSIFIED DRUG;

BREAST CANCER; DNA REPAIR; DOUBLE STRANDED DNA BREAK; HOMOLOGOUS RECOMBINATION; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW;

EID: 84873990373     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.11.013     Document Type: Review

References (106)

1. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P.A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L.M., Ding W., Bell R., Rosenthal J., Hussey C., Tran T., McClure M., Freye C., Hattier T., Phelps R., Haugen-Strano A., Katcher H., Yakumo K., Cholami Z., Shaffer D., Stone S., Bayer S., Wray C., Bogden R., Dayananth P., Ward J., Tonin P., Narod S., Bristow P.K., Norris F.H., Helvering L., Morrison P., Rosteck P., Lai M., Barrett J.C., Lewis C., Neuhausen S., Cannon-Albright L., Goldgar D., Wiseman R., Kamb A., Skolnick M.H. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266:66-71.
2. Hall J.M., Lee M.K., Newman B., Morrow J.E., Anderson L.A., Huey B., King M.C. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990, 250:1684-1689.
3. Wang Y., Cortez D., Yazdi P., Neff N., Elledge S.J., Qin J. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev. 2000, 14:927-939.
4. Deng C.X., Brodie S.G. Roles of BRCA1 and its interacting proteins. BioEssays: News Rev. Mol. Cell. Dev. Biol. 2000, 22:728-737.
5. van Attikum H., Gasser S.M. Crosstalk between histone modifications during the DNA damage response. Trends Cell Biol. 2009, 19:207-217.
6. Tutt A., Ashworth A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol. Med. 2002, 8:571-576.
7. Wu L.C., Wang Z.W., Tsan J.T., Spillman M.A., Phung A., Xu X.L., Yang M.C., Hwang L.Y., Bowcock A.M., Baer R. Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat. Genet. 1996, 14:430-440.
8. Koonin E.V., Altschul S.F., Bork P. BRCA1 protein products-functional motifs. Nat. Genet. 1996, 13:266-268.
9. Rodriguez J.A., Henderson B.R. Identification of a functional nuclear export sequence in BRCA1. J. Biol. Chem. 2000, 275:38589-38596.
10. Thakur S., Zhang H.B., Peng Y., Le H., Carroll B., Ward T., Yao J., Farid L.M., Couch F.J., Wilson R.B., Weber B.L. Localization of BRCA1 and a splice variant identifies the nuclear localization signal. Mol. Cell Biol. 1997, 17:444-452.
11. Yarden R.I., Papa M.Z. BRCA1 at the crossroad of multiple cellular pathways: approaches for therapeutic interventions. Mol. Cancer Ther. 2006, 5:1396-1404.
12. Venkitaraman A.R. Tracing the network connecting BRCA and Fanconi anemia proteins. Nat. Rev. Cancer 2004, 4:266-276.
13. Hoeijmakers J.H. Genome maintenance mechanisms for preventing cancer. Nature 2001, 411:366-374.
14. Johnson R.D., Jasin M. Sister chromatid gene conversion is a prominent double-strand break repair pathway in mammalian cells. Embo. J. 2000, 19:3398-3407.
15. Nagaraju G., Odate S., Xie A., Scully R. Differential regulation of short- and long-tract gene conversion between sister chromatids by Rad51C. Mol. Cell Biol. 2006, 26:8075-8086.
16. Weterings E., Chen D.J. The endless tale of non-homologous end-joining. Cell Res. 2008, 18:114-124.
17. Grawunder U., Zimmer D., Kulesza P., Lieber M.R. Requirement for an interaction of XRCC4 with DNA ligase IV for wild-type V(D)J recombination and DNA double-strand break repair in vivo. J. Biol. Chem. 1998, 273:24708-24714.
18. Delacote F., Lopez B.S. Importance of the cell cycle phase for the choice of the appropriate DSB repair pathway, for genome stability maintenance: the trans-S double-strand break repair model. Cell Cycle 2008, 7:33-38.
19. DeFazio L.G., Stansel R.M., Griffith J.D., Chu G. Synapsis of DNA ends by DNA-dependent protein kinase. Embo J. 2002, 21:3192-3200.
20. Ma Y., Pannicke U., Schwarz K., Lieber M.R. Hairpin opening and overhang processing by an Artemis/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination. Cell 2002, 108:781-794.
21. Ma Y., Pannicke U., Lu H., Niewolik D., Schwarz K., Lieber M.R. The DNA-dependent protein kinase catalytic subunit phosphorylation sites in human Artemis. J. Biol. Chem. 2005, 280:33839-33846.
22. Ramadan K., Shevelev I., Hubscher U. The DNA-polymerase-X family: controllers of DNA quality?. Nat. Rev. Mol. Cell Biol. 2004, 5:1038-1043.
23. Krum S.A., la Rosa Dalugdugan E., Miranda-Carboni G.A., Lane T.F. BRCA1 forms a functional complex with gamma-H2AX as a late response to genotoxic stress. J. Nucleic Acids 2010, 2010. (9 pp).
24. Rogakou E.P., Boon C., Redon C., Bonner W.M. Megabase chromatin domains involved in DNA double-strand breaks in vivo. J. Cell Biol. 1999, 146:905-916.
25. Jazayeri A., Falck J., Lukas C., Bartek J., Smith G.C., Lukas J., Jackson S.P. ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat. Cell Biol. 2006, 8:37-45.
26. Venkitaraman A.R. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002, 108:171-182.
27. Smith J., Tho L.M., Xu N., Gillespie D.A. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv. Cancer Res. 2010, 108:73-112.
28. McGowan C.H. Checking in on Cds1 (Chk2): a checkpoint kinase and tumor suppressor. BioEssays: News Rev. Mol. Cell. Dev. Biol. 2002, 24:502-511.
29. Lee J.S., Collins K.M., Brown A.L., Lee C.H., Chung J.H. hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature 2000, 404:201-204.
30. Joughin B.A., Tidor B., Yaffe M.B. A computational method for the analysis and prediction of protein:phosphopeptide-binding sites. Protein Sci.: Publ. Protein Soc. 2005, 14:131-139.
31. Yarden R.I., Pardo-Reoyo S., Sgagias M., Cowan K.H., Brody L.C. BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat. Genet. 2002, 30:285-289.
32. Karppinen S.M., Erkko H., Reini K., Pospiech H., Heikkinen K., Rapakko K., Syvaoja J.E., Winqvist R. Identification of a common polymorphism in the TopBP1 gene associated with hereditary susceptibility to breast and ovarian cancer. Eur. J. Cancer 2006, 42:2647-2652.
33. Greenberg R.A., Sobhian B., Pathania S., Cantor S.B., Nakatani Y., Livingston D.M. Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes. Genes Dev. 2006, 20:34-46.
34. Sokka M., Parkkinen S., Pospiech H., Syvaoja J.E. Function of TopBP1 in genome stability. Subcell Biochem. 2010, 50:119-141.
35. Yoo H.Y., Kumagai A., Shevchenko A., Dunphy W.G. Ataxia-telangiectasia mutated (ATM)-dependent activation of ATR occurs through phosphorylation of TopBP1 by ATM. J. Biol. Chem. 2007, 282:17501-17506.
36. Nam E.A., Cortez D. ATR signalling: more than meeting at the fork. Biochem. J. 2011, 436:527-536.
37. Morishima K., Sakamoto S., Kobayashi J., Izumi H., Suda T., Matsumoto Y., Tauchi H., Ide H., Komatsu K., Matsuura S. TopBP1 associates with NBS1 and is involved in homologous recombination repair. Biochem. Biophys. Res. Commun. 2007, 362:872-879.
38. Joukov V., Chen J., Fox E.A., Green J.B., Livingston D.M. Functional communication between endogenous BRCA1 and its partner, BARD1, during Xenopus laevis development. Proc. Natl. Acad. Sci. USA 2001, 98:12078-12083.
39. Ayi T.C., Tsan J.T., Hwang L.Y., Bowcock A.M., Baer R. Conservation of function and primary structure in the BRCA1-associated RING domain (BARD1) protein. Oncogene 1998, 17:2143-2148.
40. Yu X., Fu S., Lai M., Baer R., Chen J. BRCA1 ubiquitinates its phosphorylation-dependent binding partner CtIP. Genes Dev. 2006, 20:1721-1726.
41. Yu X., Chini C.C., He M., Mer G., Chen J. The BRCT domain is a phospho-protein binding domain. Science 2003, 302:639-642.
42. Morris J.R., Solomon E. BRCA1: BARD1 induces the formation of conjugated ubiquitin structures, dependent on K6 of ubiquitin, in cells during DNA replication and repair. Hum. Mol. Genet. 2004, 13:807-817.
43. Mallery D.L., Vandenberg C.J., Hiom K. Activation of the E3 ligase function of the BRCA1/BARD1 complex by polyubiquitin chains. EMBO J. 2002, 21:6755-6762.
44. Starita L.M., Horwitz A.A., Keogh M.C., Ishioka C., Parvin J.D., Chiba N. BRCA1/BARD1 ubiquitinate phosphorylated RNA polymerase II. J. Biol. Chem. 2005, 280:24498-24505.
45. Kleiman F.E., Manley J.L. The BARD1-CstF-50 interaction links mRNA 3' end formation to DNA damage and tumor suppression. Cell 2001, 104:743-753.
46. Baer R., Ludwig T. The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity. Curr. Opin. Genet. Dev. 2002, 12:86-91.
47. Drost R., Bouwman P., Rottenberg S., Boon U., Schut E., Klarenbeek S., Klijn C., van der Heijden I., van der Gulden H., Wientjens E., Pieterse M., Catteau A., Green P., Solomon E., Morris J.R., Jonkers J. BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell 2011, 20:797-809.
48. Shakya R., Reid L.J., Reczek C.R., Cole F., Egli D., Lin C.S., deRooij D.G., Hirsch S., Ravi K., Hicks J.B., Szabolcs M., Jasin M., Baer R., Ludwig T. BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity. Science 2011, 334:525-528.
49. Rouleau M., Patel A., Hendzel M.J., Kaufmann S.H., Poirier G.G. PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer 2010, 10:293-301.
50. Cantor S.B., Andreassen P.R. Assessing the link between BACH1 and BRCA1 in the FA pathway. Cell Cycle 2006, 5:164-167.
51. Baumann P., Benson F.E., West S.C. Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro. Cell 1996, 87:757-766.
52. Kumaraswamy E., Shiekhattar R. Activation of BRCA1/BRCA2-associated helicase BACH1 is required for timely progression through S phase. Mol. Cell Biol. 2007, 27:6733-6741.
53. Peng M., Litman R., Jin Z., Fong G., Cantor S.B. BACH1 is a DNA repair protein supporting BRCA1 damage response. Oncogene 2006, 25:2245-2253.
54. Narod S.A., Foulkes W.D. BRCA1 and BRCA2: 1994 and beyond. Nat. Rev. Cancer 2004, 4:665-676.
55. Bochar D.A., Wang L., Beniya H., Kinev A., Xue Y., Lane W.S., Wang W., Kashanchi F., Shiekhattar R. BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell 2000, 102:257-265.
56. Carlson M., Osmond B.C., Botstein D. Mutants of yeast defective in sucrose utilization. Genetics 1981, 98:25-40.
57. Harte M.T., O'Brien G.J., Ryan N.M., Gorski J.J., Savage K.I., Crawford N.T., Mullan P.B., Harkin D.P. BRD7, a subunit of SWI/SNF complexes, binds directly to BRCA1 and regulates BRCA1-dependent transcription. Cancer Res. 2010, 70:2538-2547.
58. Yu X., Chen J. DNA damage-induced cell cycle checkpoint control requires CtIP, a phosphorylation-dependent binding partner of BRCA1 C-terminal domains. Mol. Cell. Biol. 2004, 24:9478-9486.
59. Stauffer M.E., Chazin W.J. Physical interaction between replication protein A and Rad51 promotes exchange on single-stranded DNA. J. Biol. Chem. 2004, 279:25638-25645.
60. Li X., Heyer W.D. Homologous recombination in DNA repair and DNA damage tolerance. Cell Res. 2008, 18:99-113.
61. Peterson S.E., Li Y., Chait B.T., Gottesman M.E., Baer R., Gautier J. Cdk1 uncouples CtIP-dependent resection and Rad51 filament formation during M-phase double-strand break repair. J. Cell Biol. 2011, 194:705-720.
62. Wang H., Shao Z., Shi L.Z., Hwang P.Y., Truong L.N., Berns M.W., Chen D.J., Wu X. CtIP dimerization is critical for its recruitment to chromosomal DNA double-strand breaks. J. Biol. Chem. 2012.
63. Wu X.H., Ranganathan V., Weisman D.S., Heine W.F., Ciccone D.N., O'Neill T.B., Crick K.E., Pierce K.A., Lane W.S., Rathbum G., Livingston D.M., Weaver D.T. ATM phosphorylation of Nijmegen breakage syndrome protein is required in a DNA damage response. Nature 2000, 405:477-482.
64. Haber J.E. The many interfaces of Mre11. Cell 1998, 95:583-586.
65. Yuan J.S., Chen J.J. MRE11-RAD50-NBS1 complex dictates DNA repair independent of H2AX. J. Biol. Chem. 2010, 285:1097-1104.
66. Wang B., Matsuoka S., Ballif B.A., Zhang D., Smogorzewska A., Gygi S.P., Elledge S.J. Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science 2007, 316:1194-1198.
67. Yan J., Yang X.P., Kim Y.S., Joo J.H., Jetten A.M. RAP80 interacts with the SUMO-conjugating enzyme UBC9 and is a novel target for sumoylation. Biochem. Biophys. Res. Commun. 2007, 362:132-138.
68. Kim H., Chen J., Yu X. Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response. Science 2007, 316:1202-1205.
69. Wu J., Huen M.S., Lu L.Y., Ye L., Dou Y., Ljungman M., Chen J., Yu X. Histone ubiquitination associates with BRCA1-dependent DNA damage response. Mol. Cell. Biol. 2009, 29:849-860.
70. Yan J., Kim Y.S., Yang X.P., Li L.P., Liao G., Xia F., Jetten A.M. The ubiquitin-interacting motif containing protein RAP80 interacts with BRCA1 and functions in DNA damage repair response. Cancer Res. 2007, 67:6647-6656.
71. Yan J., Jetten A.M. RAP80 and RNF8, key players in the recruitment of repair proteins to DNA damage sites. Cancer Lett. 2008, 271:179-190.
72. Sobhian B., Shao G., Lilli D.R., Culhane A.C., Moreau L.A., Xia B., Livingston D.M., Greenberg R.A. RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. Science 2007, 316:1198-1202.
73. Hu Y., Scully R., Sobhian B., Xie A., Shestakova E., Livingston D.M. RAP80-directed tuning of BRCA1 homologous recombination function at ionizing radiation-induced nuclear foci. Genes Dev. 2011, 25:685-700.
74. Zhang F., Fan Q., Ren K., Andreassen P.R. PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2. Mol. Cancer Res. 2009, 7:1110-1118.
75. Xia B., Sheng Q., Nakanishi K., Ohashi A., Wu J., Christ N., Liu X., Jasin M., Couch F.J., Livingston D.M. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol. Cell 2006, 22:719-729.
76. Sy S.M., Huen M.S., Chen J. PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc. Natl. Acad. Sci. USA 2009, 106:7155-7160.
77. Scully R., Chen J., Plug A., Xiao Y., Weaver D., Feunteun J., Ashley T., Livingston D.M. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997, 88:265-275.
78. Chen J., Silver D.P., Walpita D., Cantor S.B., Gazdar A.F., Tomlinson G., Couch F.J., Weber B.L., Ashley T., Livingston D.M., Scully R. Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol. Cell 1998, 2:317-328.
79. San Filippo J., Chi P., Sehorn M.G., Etchin J., Krejci L., Sung P. Recombination mediator and Rad51 targeting activities of a human BRCA2 polypeptide. J. Biol. Chem. 2006, 281:11649-11657.
80. Bhattacharyya A., Ear U.S., Koller B.H., Weichselbaum R.R., Bishop D.K. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J. Biol. Chem. 2000, 275:23899-23903.
81. Joenje H., Patel K.J. The emerging genetic and molecular basis of Fanconi anemia. Nat. Rev. Genet. 2001, 2:446-457.
82. Garcia-Higuera I., Taniguchi T., Ganesan S., Meyn M.S., Timmers C., Hejna J., Grompe M., D'Andrea A.D. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol. Cell 2001, 7:249-262.
83. Taniguchi T., Garcia-Higuera I., Andreassen P.R., Gregory R.C., Grompe M., D'Andrea A.D. S-phase-specific interaction of the Fanconi anemia protein FANCD2, with BRCA1 and RAD51. Blood 2002, 100:2414-2420.
84. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
85. Wooster R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J., Collins N., Gregory S., Gumbs C., Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995, 378:789-792.
86. Banerjee S., Kaye S.B., Ashworth A. Making the best of PARP inhibitors in ovarian cancer. Nat. Rev. Clin. Oncol. 2010, 7:508-519.
87. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., Kyle S., Meuth M., Curtin N.J., Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917.
88. Moynahan M.E., Chiu J.W., Koller B.H., Jasin M. Brca1 controls homology-directed DNA repair. Mol. Cell 1999, 4:511-518.
89. Moynahan M.E., Cui T.Y., Jasin M. Homology-directed DNA repair, mitomycin-C resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res. 2001, 61:4842-4850.
90. Gough C.A., Gojobori T., Imanishi T. Cancer-related mutations in BRCA1-BRCT cause long-range structural changes in protein-protein binding sites: a molecular dynamics study. Proteins 2007, 66:69-86.
91. Chapman M.S., Verma I.M. Transcriptional activation by BRCA1. Nature 1996, 382:678-679.
92. Brody L.C., Yarden R.I. BRCA1 interacts with components of the histone deacetylase complex. Proc. Nat. Acad. Sci. USA 1999, 96:4983-4988.
93. Lee M.S., Green R., Marsillac S.M., Coquelle N., Williams R.S., Yeung T., Foo D., Hau D.D., Hui B., Monteiro A.N., Glover J.N. Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays. Cancer Res. 2010, 70:4880-4890.
94. Baer R., Yu X., Wu L.J.C., Bowcock A.M., Aronheim A. The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression. J. Biol. Chem. 1998, 273:25388-25392.
95. Wong A.K., Ormonde P.A., Pero R., Chen Y., Lian L., Salada G., Berry S., Lawrence Q., Dayananth P., Ha P., Tavtigian S.V., Teng D.H., Bartel P.L. Characterization of a carboxy-terminal BRCA1 interacting protein. Oncogene 1998, 17:2279-2285.
96. Pessetto Z.Y., Yan Y., Bessho T., Natarajan A. Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option. Breast Cancer Res. Treat. 2012, 134:511-517.
97. Evers B., Jonkers J. Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects. Oncogene 2006, 25:5885-5897.
98. Bouwman P., Aly A., Escandell J.M., Pieterse M., Bartkova J., van der Gulden H., Hiddingh S., Thanasoula M., Kulkarni A., Yang Q., Haffty B.G., Tommiska J., Blomqvist C., Drapkin R., Adams D.J., Nevanlinna H., Bartek J., Tarsounas M., Ganesan S., Jonkers J. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat. Struct. Mol. Biol. 2010, 17:688-695.
99. Cao L., Xu X., Bunting S.F., Liu J., Wang R.H., Cao L.L., Wu J.J., Peng T.N., Chen J., Nussenzweig A., Deng C.X., Finkel T. A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency. Mol. Cell 2009, 35:534-541.
100. Bunting S.F., Callen E., Wong N., Chen H.T., Polato F., Gunn A., Bothmer A., Feldhahn N., Fernandez-Capetillo O., Cao L., Xu X., Deng C.X., Finkel T., Nussenzweig M., Stark J.M., Nussenzweig A. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 2010, 141:243-254.
101. Xie A., Hartlerode A., Stucki M., Odate S., Puget N., Kwok A., Nagaraju G., Yan C., Alt F.W., Chen J., Jackson S.P., Scully R. Distinct roles of chromatin-associated proteins MDC1 and 53BP1 in mammalian double-strand break repair. Mol. Cell 2007, 28:1045-1057.
102. Moynahan M.E., Jasin M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat. Rev. Mol. Cell. Biol. 2010, 11:196-207.
103. Brzovic P.S., Meza J., King M.C., Klevit R.E. The cancer-predisposing mutation C61G disrupts homodimer formation in the NH2-terminal BRCA1 RING finger domain. J. Biol. Chem. 1998, 273:7795-7799.
104. Willems P., Magri V., Cretnik M., Fasano M., Jakubowska A., Levanat S., Lubinski J., Marras E., Musani V., Thierens H., Vandersickel V., Perletti G., Vral A. Characterization of the c.190 T>C missense mutation in BRCA1 codon 64 (Cys64Arg). Int. J. Oncol. 2009, 34:1005-1015.
105. Atipairin A., Canyuk B., Ratanaphan A. Substitution of aspartic acid with glutamic acid at position 67 of the BRCA1 RING domain retains ubiquitin ligase activity and zinc(II) binding with a reduced transition temperature. J. Biol. Inorg. Chem. 2011, 16:217-226.
106. Nelson A.C., Holt J.T. Impact of RING and BRCT domain mutations on BRCA1 protein stability, localization and recruitment to DNA damage. Radiat. Res. 2010, 174:1-13.